PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Samsara Inc. (IOT)
33.600.80 (-2.33%)
33.44 - 34.57
31.40 - 61.90
7.61M / 5.95M (Avg.)
-152.73 | -0.22
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
7.55%
Revenue growth 1.25-1.5x BRZE's 5.49%. Bruce Berkowitz would check if differentiation or pricing power justifies outperformance.
8.14%
Gross profit growth above 1.5x BRZE's 4.66%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
60.83%
EBIT growth above 1.5x BRZE's 33.81%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
61.13%
Operating income growth above 1.5x BRZE's 33.81%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
70.37%
Net income growth above 1.5x BRZE's 38.40%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
-110.47%
Negative EPS growth while BRZE is at 37.04%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-110.47%
Negative diluted EPS growth while BRZE is at 37.04%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.84%
Share count expansion well above BRZE's 0.76%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.84%
Diluted share count expanding well above BRZE's 0.76%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
49.55%
OCF growth under 50% of BRZE's 249.72%. Michael Burry might suspect questionable revenue recognition or rising costs.
55.30%
FCF growth under 50% of BRZE's 206.72%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
88.33%
10Y revenue/share CAGR under 50% of BRZE's 227.66%. Michael Burry would suspect a lasting competitive disadvantage.
88.33%
5Y revenue/share CAGR under 50% of BRZE's 227.66%. Michael Burry would suspect a significant competitive gap or product weakness.
35.59%
3Y revenue/share CAGR under 50% of BRZE's 105.71%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
166.35%
10Y OCF/share CAGR under 50% of BRZE's 74806.28%. Michael Burry would worry about a persistent underperformance in cash creation.
166.35%
Below 50% of BRZE's 74806.28%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
154.90%
3Y OCF/share CAGR similar to BRZE's 162.91%. Walter Schloss might see both benefiting from a rising tide or parallel expansions.
87.21%
Positive 10Y CAGR while BRZE is negative. John Neff might see a substantial advantage in bottom-line trajectory.
87.21%
Positive 5Y CAGR while BRZE is negative. John Neff might view this as a strong mid-term relative advantage.
97.82%
3Y net income/share CAGR above 1.5x BRZE's 64.17%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
182.87%
Below 50% of BRZE's 483.79%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
182.87%
Below 50% of BRZE's 483.79%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-46.77%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.94%
AR growth well above BRZE's 12.92%. Michael Burry fears inflated revenue or higher default risk in the near future.
-1.16%
Inventory is declining while BRZE stands at 0.00%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
8.61%
Asset growth above 1.5x BRZE's 3.44%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
6.12%
BV/share growth above 1.5x BRZE's 2.92%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-6.60%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-4.82%
Our R&D shrinks while BRZE invests at 2.27%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-1.35%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.